CLINICAL FEATURES OF THE NEUROMYELITIS OPTICA SPECTRUM DISORDER

Nguyễn Văn Tuận1,2,, Nguyễn Văn Sỹ3
1 Bach Mai Hospital
2 University of Medicine and Pharmacy, Vietnam National University, Hanoi
3 Hanoi Medical University

Main Article Content

Abstract

Objective: To describe the clinical features of neuromyelitis optica spectrum disorder (NMOSD). Subjects and methods: We studied 42 patients who were treated at the Neurology Center of Bach Mai hospital and were diagnosed with NMOSD. Results: The disease mainly affects women (80.1%), female/male ratio of 4:1. Mean age of onset was 36.3 ± 12.1. The comorbidities with other autoimmune diseases are 15.2%. There were 90.5% of patients relapsed. Common symptoms are a loss of bilateral visual acuity 45.2%, motor paralysis and sensory disturbances 90.5%, urination disorder 66.7%, in addition, other symptoms are less common such as involuntary muscle contractions 19%, cerebellar damage 14.2%, cranial nerve palsy 19%, vomiting, hiccups 23.8%. Patients were diagnosed with NMOSD based on anti-aquaporin 4 antibody test with acute myelitis and optic neuritis 83.3%, Postrema area 11.9%, brain stem/cerebellar syndrome 14.3%, simple optic neuritis 4.8%, diencephalic lesions 4.8%. Conclusion: Clinical symptoms correspond to acute spinal cord injury, and optic neuritis, in addition, there are lesions in the brainstem, diencephalic and cerebral hemispheres.

Article Details

References

1. Lê Văn Thủy, Vũ Hồng Vân, Nguyễn Thị Hiền, Đỗ Thị Hà, Nguyễn Văn Hướng. Đặc điểm lâm sàng, hình ảnh học cộng hưởng từ và tính an toàn của Rituximab liều thấp trên các trường hợp mắc phổ bệnh lý viêm tuỷ thị thần kinh. Nghiên Cứu Y Học (Đại Học Y Hà Nội). 2020;134(10):248-256.
2. Bukhari W, Clarke L, O’Gorman C, et al. The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology. 2020/01/31 2020;doi:10.1007/s00415-020-09716-4
3. Cree BA, Hauser SL. Neuromyelitis Optica. In: Harrison's Principles of Internal Medicine. 20th Ed.: Mc Graw Hll Education; 2018, chapter 437.
4. Houzen H, Kondo K, Niino M, et al. Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology. 2017;89(19):1995-2001. doi:10.1212/wnl.0000000000004611
5. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
6. Lotan I, Bacon T, Kister I, Levy M. Paroxysmal symptoms in neuromyelitis optica spectrum disorder: Results from an online patient survey. Mult Scler Relat Disord. Nov 2020;46:102578. doi:10.1016/j.msard.2020.102578
7. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Archives of neurology. Sep 2012;69(9):1176-80. doi:10.1001/archneurol.2012.314
8. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/ WNL.0000000000001729